CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 7, 2024
app pub date -
Aug 8, 2022
filing date -
Aug 8, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a cancer-specific trans-splicing ribozyme as a gene therapy product combined with radiotherapy. The ribozyme of the present disclosure is safe because of the cancer tissue-specific expression thereof and exhibits high expression efficiency at a post-transcriptional level and thus can be provided as a safe and effective gene therapy product. When administered after radiotherapy, the ribozyme exhibits high anticancer effects even at a low dose of radiation and a low dose of gene therapy product and thus is expected to be used in a cancer therapy method and a radiation-resistant cancer therapy method with no or little adverse effects.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully